Opinion|Videos|April 16, 2025
Overcoming Inertia in Hypercortisolism Identification
Experts discuss how hypercortisolism affects health care utilization and costs for patients, comparing it with patients with other chronic diseases, and how our understanding of the clinical presentation of hypercortisolism has evolved, distinguishing overt hallmark symptoms from nonspecific features overlapping with chronic disease.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does hypercortisolism affect health care utilization and costs for patients?
- How does this compare with patients with other chronic diseases?
- How has our understanding of the clinical presentation of hypercortisolism evolved?
- Overt, hallmark symptoms and features vs nonspecific features and symptoms overlapping with chronic disease
Advertisement
Related to this article
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
3
Advances in Treating High-Impact Psoriasis from EADV 2026
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines Based on HYPERION Data
5